Welcome to our dedicated page for ATRS news (Ticker: ATRS), a resource for investors and traders seeking the latest updates and insights on ATRS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ATRS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ATRS's position in the market.
Antares Pharma has formalized the sale of its OTREXUP injection product to Assertio Holdings for $44 million, enhancing its financial strength. The deal includes an initial $18 million payment and two further payments of $26 million in 2022. Antares aims to focus on developing its urology and endocrinology portfolio, including products like XYOSTED and TLANDO, as it aligns its sales efforts. This strategic divestiture allows Antares to better target its commercial resources and streamline operations, pivotal for future growth and maintaining product accessibility for patients.
Antares Pharma (NASDAQ: ATRS) announced that CEO Robert F. Apple will present and hold investor meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. A pre-recorded webcast of the fireside chat will be accessible on the Antares Pharma website starting November 22 at 10 am ET. The company specializes in developing self-administered injectable products and has FDA-approved offerings such as XYOSTED® and OTREXUP®. Future product launches include TLANDO®, pending FDA approval.
Antares Pharma, a specialty pharmaceutical company, announced that CEO Robert F. Apple will present at the Jefferies London Healthcare Conference from November 16-19, 2021. The presentation is scheduled for November 18 at 7:00 am ET and will include a fireside chat and one-on-one meetings. A webcast will be available on their website. Antares Pharma focuses on developing self-administered injectable products and has partnerships with major pharmaceutical companies. Their FDA-approved products include XYOSTED, OTREXUP, and NOCDURNA.
Antares Pharma reported a strong third quarter for 2021, with total revenue reaching $48.2 million, a 20% increase year-over-year. The company achieved a net income of $5.4 million, maintaining earnings per share at $0.03. Key drivers included a 40% increase in prescriptions for XYOSTED and a 91% rise in EpiPen prescriptions. Antares also signed a license agreement for TLANDO, enhancing its testosterone portfolio. The company updated its revenue guidance for 2021 to $180-190 million, projecting 20-27% growth year-over-year.
Antares Pharma announced the appointment of Carmen Volkart to its Board of Directors, where she will also serve on the Audit Committee. Volkart has extensive experience in finance and operations, previously serving as CFO at NatureWorks and NxThera. Her diverse background in the healthcare sector is expected to bolster Antares' growth initiatives. Chairman Leonard S. Jacob expressed confidence in her contributions to the company’s objectives. Antares focuses on developing self-administered injectable products and has several FDA-approved products and partnerships.
Antares Pharma, Inc. (NASDAQ: ATRS) announced that their abstract on XYOSTED®, a testosterone enanthate injection, was accepted for oral presentation at the 22nd Annual Fall Scientific Meeting of SMSNA, held from October 21-24, 2021, in Scottsdale, AZ. The presentation focused on the relationship between body mass index (BMI) and serum testosterone levels in men with testosterone deficiency. Findings suggest that higher BMI may necessitate increased testosterone dosages. Antares Pharma's XYOSTED® offers flexibility in dosing with strengths of 50 mg, 75 mg, and 100 mg.
Antares Pharma, a specialty pharmaceutical company, will announce its Q3 2021 financial and operational results on November 4, 2021, prior to market opening. A conference call will be held the same day at 8:30am ET, with dial-in numbers for domestic and international callers. Antares focuses on self-administered injectable products and has partnerships with major pharmaceutical companies. Its FDA-approved products include XYOSTED and OTREXUP, with upcoming launches for TLANDO and NOCDURNA anticipated pending FDA approvals.
Antares Pharma, Inc. has entered into an exclusive licensing agreement with Lipocine Inc. for TLANDO®, an oral testosterone replacement therapy. The FDA granted tentative approval for TLANDO®, which targets hypogonadism in adult males. The agreement involves an upfront payment of $11 million and additional milestone payments totaling up to $10 million, alongside royalties based on sales. Additionally, Antares has the option to license TLANDO XR, a potential once-daily oral testosterone product. The market for testosterone therapy is expanding, enhancing Antares's growth prospects.
Antares Pharma has begun a Phase 1 study for ATRS-1902, focusing on adrenal crisis rescue treatment using a new auto-injector platform. This innovative platform delivers a liquid stable formulation of hydrocortisone, eliminating the need for reconstitution. The study seeks to establish the safety, tolerability, and pharmacokinetics of ATRS-1902, comparing it with Solu-Cortef. Results are expected in 1Q 2022, and the company aims to submit a 505(b)(2) NDA to the FDA if results are favorable.
Antares Pharma, Inc. (NASDAQ: ATRS) has announced that CEO Robert F. Apple will participate in investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. The company specializes in developing and commercializing self-administered injectable pharmaceutical products, utilizing innovative auto-injector technology. Antares has a diverse product portfolio, including FDA-approved products like XYOSTED® and OTREXUP®, and has strategic partnerships with major pharmaceutical companies like Teva and Pfizer.
FAQ
What is the market cap of ATRS (ATRS)?
